enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves 1st new drug for schizophrenia in more ... - AOL

   www.aol.com/fda-approves-1st-drug-schizophrenia...

   Loaded 0%. The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers ...

3. Bristol Myers wins US FDA approval for new type of ...

   www.aol.com/news/us-fda-approves-bristol-myers...

   September 27, 2024 at 6:06 AM. By Bhanvi Satija and Michael Erman. (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it ...

4. New schizophrenia drug gets FDA approval, taking novel ... - AOL

   www.aol.com/news/schizophrenia-drug-gets-fda...

   September 27, 2024 at 2:25 PM. New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder. A new drug has been approved for the treatment of schizophrenia in adults ...

5. Paliperidone - Wikipedia

   en.wikipedia.org/wiki/Paliperidone

   Paliperidone was approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in December 2006, [4] and in the European Union in June 2007. [8] Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester. [14] [15] It is on the World Health Organization's List of Essential Medicines ...

6. Aripiprazole - Wikipedia

   en.wikipedia.org/wiki/Aripiprazole

   Aribit (Aripiprazole) tablets. Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. [8] It is primarily used in the treatment of schizophrenia and bipolar disorder; [8] other uses include as an add-on treatment in major depressive disorder and obsessive–compulsive disorder (OCD), tic disorders, and irritability associated with autism. [8]

7. Ulotaront - Wikipedia

   en.wikipedia.org/wiki/Ulotaront

   Ulotaront (INN; [1] developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. [2][3] The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals [2] (which was subsequently merged ...